Trandolapril, CAS number 87679-37-6, is intended for patients with hypertension, or for anyone who has experienced heart failure post myocardial infarction. Particularly effective for those patients who have left-ventricular dysfunction after a heart attack, trandolapril is an angiotensin-converting enzyme, or ACE inhibitor. Marketed by Abbott as the brand name Mavik, the patent for this lifesaving medication is due to expire on April 28, 2015. Available in 1, 2 or 4 milligram tablets, trandolapril is typically taken as 2-4 milligrams once daily, if the patient is not taking additional diuretics. Side effects tend to be mild, and may include muscle pain, cough and dizziness.
Race matters in terms of dosing patients with trandolapril. Patients who are African American should start their dose at 2 milligrams daily, providing they are not taking a diuretic. Caucasian patients should begin their dose at 1 milligram daily, also as long as they do not take a diuretic. All patients, regardless of race should be titrated over time, receiving increased dosing based on one week intervals. The maximum safe dose is 8 milligrams, given in two divided doses.
Pharmaceutical success has been found with mavik, or trandolapril, as Abbott reported better than expected first quarter revenue and income on April 18, 2012. Profits were up 44% from $864 million dollars to $1.24 billion dollars. In the press release it was announced that this monumental gain was due in part to their cardiovascular line of products, including trandolapril (Mavik).
One of many successful clinical trials involved patients who were considered stable, 3 to 7 days after myocardial infarction and showed left ventricular dysfunction. This trial, deemed TRACE, or Trandolapril Cardiac Evaluation, involved a 27-center Danish study. The trial was a double-blind, placebo controlled, and parallel-group study. Participants with residual ischemia and heart failure were included. The group of patients who tolerated the initial dose of 1 milligram were then randomized to either a placebo or trandolapril, and followed for 24 months. The 876 patients who received trandolapril experienced an average 16% risk reduction in mortality. Of the patients who required a higher dose of trandolapril, 62% were eventually administered 4 milligrams, once daily. All patients who were given trandolapril also saw a 20% overall risk reduction for the progression of heart failure. LGM Pharma is a provider of the API trandolapril for research and development purposes. Total support is offered to clients for all R&D needs.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.